History Back
2011
07-21
S&P Pharmaceutical Co Ltd's Application of Non-Public Offering Approved by CSRC - Grandall Shanghai Office Acted as Issuer's Counsel
July 20, 2011 - Shanghai, China - The application for non-public offering of S&P Pharmaceutical Co., Ltd. (“S&P”) was passed and approved by the Securities Public Offering Examination and Approval Committee of China Securities Regulatory Commission (“CSRC”) on July 20, 2011.
S&P intends to offer to the particular investors a limited number of 72,000,000 shares, the total amount of which is not more than RMB1,484,694,200. The funds, amounting to RMB1,448,868,900 (after deducting the issuance fees) is raised to invest in five projects, including cables for renewable energy source like wind power, nuclear power and solar energy, smart grid EHV cables and other cable projects.
Grandall Shanghai Office has been retained as the Issuer's Counsel. The project is led by Mr. Liu Wei, a partner of Grandall, and Ms. Wei Wei, Mr. Xu Junyi together with Ms. Song Pingping are the key Grandall attorneys servicing S&P.
Click here to find out more: S&P Pharmaceutical Co., Ltd.